Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.
Mach F, Visseren FLJ, Cater NB, Salhi N, Soronen J, Ray KK, Delgado V, Jukema JW, Laufs U, Zamorano JL, Ros E, Plat J, Gesztes AG, Tokgozoglu L, Packard C, Libby P. Mach F, et al. Among authors: cater nb. J Clin Lipidol. 2024 Jul 6:S1933-2874(24)00209-5. doi: 10.1016/j.jacl.2024.07.001. Online ahead of print. J Clin Lipidol. 2024. PMID: 39289123 Review.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Corbin KD, Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Frederich R, Liu J, Pong A, Lin J, Cater NB, Pratley RE. Corbin KD, et al. Among authors: cater nb. Diabetes Obes Metab. 2023 Mar;25(3):758-766. doi: 10.1111/dom.14923. Epub 2022 Dec 26. Diabetes Obes Metab. 2023. PMID: 36394384 Clinical Trial.
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Kim JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, Cosentino F, McGuire DK, Pratley RE, Liu CC, Cater NB, Frederich R, Mancuso JP, Cannon CP. Kim JM, et al. Among authors: cater nb. Diabetes Obes Metab. 2023 May;25(5):1398-1402. doi: 10.1111/dom.14965. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36594154 No abstract available.
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
Sridhar VS, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Cater NB, Noyes Essex M, Mancuso JP, Zhao Y, Cherney DZI. Sridhar VS, et al. Among authors: cater nb. Diabetes Obes Metab. 2024 Nov;26(11):5336-5346. doi: 10.1111/dom.15895. Epub 2024 Sep 2. Diabetes Obes Metab. 2024. PMID: 39219437 Clinical Trial.
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Pandey A, Kolkailah AA, Cosentino F, Cannon CP, Frederich RC, Cherney DZI, Dagogo-Jack S, Pratley RE, Cater NB, Gantz I, Mancuso JP, McGuire DK. Pandey A, et al. Among authors: cater nb. Eur Heart J. 2023 Dec 21;44(48):5163-5166. doi: 10.1093/eurheartj/ehad639. Eur Heart J. 2023. PMID: 37864578 Free PMC article. No abstract available.
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
Cosentino F, Cannon CP, Frederich R, Cherney DZI, Dagogo-Jack S, Pratley RE, Mancuso JP, Maldonado M, Cater NB, Wang S, McGuire DK. Cosentino F, et al. Among authors: cater nb. Circulation. 2022 Aug 23;146(8):652-654. doi: 10.1161/CIRCULATIONAHA.121.058294. Epub 2022 Aug 22. Circulation. 2022. PMID: 35994565 Free PMC article. Clinical Trial. No abstract available.
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Segar MW, Kolkailah AA, Frederich R, Pong A, Cannon CP, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Liu CC, Maldonado M, Liu J, Cater NB, Pandey A, Cherney DZI. Segar MW, et al. Among authors: cater nb. Diabetes Obes Metab. 2022 Sep;24(9):1829-1839. doi: 10.1111/dom.14769. Epub 2022 Jun 15. Diabetes Obes Metab. 2022. PMID: 35603908 Free PMC article. Clinical Trial.
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Wojeck BS, et al. Among authors: cater nb. Sleep Breath. 2023 May;27(2):669-672. doi: 10.1007/s11325-022-02594-2. Epub 2022 May 20. Sleep Breath. 2023. PMID: 35596030 Free PMC article. Clinical Trial.
29 results